International Takotsubo Registry (InterTAK Registry) (InterTAK)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01947621|
Recruitment Status : Recruiting
First Posted : September 20, 2013
Last Update Posted : May 21, 2014
This is a multicenter, multinational, prospective and retrospective, observational study of patients with Takotsubo cardiomyopathy (TTC).
Data on natural profile (demographical characteristics, clinical phenotype, laboratory values, electrocardiography parameters, echocardiography parameters, coronary angiography parameters, medication) and outcome are systematically collected.
Our aim is to gain a better insight into the clinical profile and pathophysiology of TTC.
|Condition or disease|
Registry is an open-ended study and eligible individuals are assessed at index event and follow-up on their phenotypical characteristics. Furthermore, outcome data are collected (by clinical visits or telephone follow-up).
In addition, participants are given the option to consent to the donation of biosamples for the purposes to identify TTC specific biomarkers and mutations (sub-study on behalf of the registry).
|Study Type :||Observational|
|Estimated Enrollment :||4000 participants|
|Official Title:||International Multicenter Registry on Takotsubo Cardiomyopathy|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||October 2014|
|Estimated Study Completion Date :||December 2020|
- Natural history of TTC [ Time Frame: 10 years ]To determine the natural history of Takotsubo cardiomyopathy.
- Cardiovascular complications, recurrence of TTC and all cause mortality [ Time Frame: at hospitalizsation, short term (1 year) and long term (10 years) ]Patients will be assessed for cardiovascular complications during hospitalisation and at follow-up (up to 10 years)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01947621
|Contact: Christian Templin, MD, PhD||+41 44 255 95 firstname.lastname@example.org|
|University Hospital Zurich, Division of Cardiology||Recruiting|
|Zurich, ZH, Switzerland, 8091|
|Principal Investigator:||Christian Templin, MD, PhD||University Hospital Zurich, Division of Cardiology|